Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
ORTHO-NOVUM 7/7/7-28 is an oral contraceptive tablet containing a triphasic norgestimate/ethinyl estradiol formulation approved in 1984. It is indicated for pregnancy prevention in women of reproductive age. The product works by suppressing ovulation through hormonal mechanisms typical of combined oral contraceptives.
Product approaching loss of exclusivity with moderate competitive pressure (30) suggests defensive commercial posture and potential team restructuring or reallocation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings indicate minimal active recruitment for this product; working on ORTHO-NOVUM 7/7/7-28 offers limited upside for career acceleration in a mature, declining franchise. Career value lies in managing market erosion and cost optimization rather than innovation or market expansion.
Worked on ORTHO-NOVUM 7/7/7-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.